Palisade Bio Inc. (PALI)
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
📉 **NEGATIVE** • Medium confidence analysis (65%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (22%) **Content type:** Clinical